Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
7.99
-0.24 (-2.92%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Company Description
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States.
The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer.
The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015.
Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Actuate Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Aug 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Daniel Schmitt |
Contact Details
Address: 1751 River Run, Suite 400 Fort Worth, Texas 76107 United States | |
| Phone | 817 887 8455 |
| Website | actuatetherapeutics.com |
Stock Details
| Ticker Symbol | ACTU |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001652935 |
| CUSIP Number | 005083100 |
| ISIN Number | US0050831009 |
| Employer ID | 47-3044785 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel M. Schmitt | Chief Executive Officer, President and Director |
| Dr. Andrew P. Mazar Ph.D. | Co-Founder and Chief Operating Officer |
| Paul J. Lytle CPA | Chief Financial Officer |
| Dr. Alan Kozikowski Ph.D. | Scientific Founder and Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | EFFECT | Notice of Effectiveness |
| Apr 16, 2025 | 424B3 | Prospectus |
| Apr 10, 2025 | D | Notice of Exempt Offering of Securities |
| Apr 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 10-K | Annual Report |
| Feb 7, 2025 | 8-K | Current Report |
| Dec 17, 2024 | 8-K | Current Report |